Bronchiectasis and COPD Patients in US Face High Financial Burden, Study Says

Bronchiectasis and COPD Patients in US Face High Financial Burden, Study Says
The financial burden associated with healthcare costs is relatively high for U.S. patients with chronic obstructive pulmonary disease (COPD) or bronchiectasis, especially for those who are affected by both disorders, a study reports. The study, "Health-care utilization and expenditures among patients with comorbid bronchiectasis and chronic obstructive pulmonary disease in US clinical practice," was published in Chronic Respiratory Disease. Bronchiectasis and COPD are two chronic respiratory diseases that can coexist in a patient, a medical condition known as bronchiectasis-COPD overlap syndrome. "There is growing recognition that BE [bronchiectasis], either by itself or combined with chronic obstructive pulmonary disease (COPD), represents a growing burden on the U.S. health-care system, which has raised calls for increased surveillance in primary care. The prevalence of COPD within BE is reported to range from 26% to 69%," the authors wrote. However, not much is known regarding the financial burden faced by patients with bronchiectasis or bronchiectasis-COPD overlap syndrome living in the U.S. This retrospective matched-cohort study gathered healthcare data from U.S. patients with bronchiectasis, COPD, or bronchiectasis-COPD overlap syndrome that had been stored at the Truven Health Analytics MarketScan Commercial Claims and Encounters, and Medicare Supplemental and Coordination of Benefits databases between 2009 and 2013. The total annual rate of healthcare utilization and expenditures for 2013, as well as the annual rate specifically associated with respiratory complications from the same year, were determined for each group of patients. The study involved a total of 679,679 patients, including 15,573 with bronchiectasis, 648,652 with COPD,
Subscribe or log in to read the rest of this content.